David W. Kimmel

TL;DR: Combined loss of 1p and 19q is a statistically significant predictor of prolonged survival in patients with pure oligodendroglioma, independent of tumor grade, and could potentially improve existing strategies for patient stratification and management.

TL;DR: Seropositivity for ANNA-1 can expedite the diagnosis and treatment of otherwise occult cancer in patients, especially tobacco abusers, with varied neurologic and gastroenterologic presentations.

TL;DR: Using 115 human diffuse gliomas, regions of common allelic loss on chromosomes 1 and 19 were localized and the association of these deletion intervals with glioma histological subtypes was assessed, suggesting not only locations of putative tumor suppressor genes, but also a simple assay for assessment of 1p and 19q alterations as diagnostic and prognostic markers.

TL;DR: It is suggested that grade 3 and 4 tumors are more likely to contain an abnormal clone than tumors of grade 1 or 2 (p less than 0.01), and cytogenetic studies can be successful on nearly all human gliomas, including those derived from small stereotactic biopsies.

TL;DR: Aggressive immunosuppression early in the clinical course should be considered in patients who have paraneoplastic neurological disorders, even when there is no evidence of active malignancy.